NASDAQ: UTMD
Utah Medical Products Inc Stock

$60.43+0.57 (+0.95%)
Updated Feb 10, 2025
UTMD Price
$60.43
Fair Value Price
$125.96
Market Cap
$204.96M
52 Week Low
$58.88
52 Week High
$77.33
P/E
14.15x
P/B
1.65x
P/S
5.28x
PEG
6.55x
Dividend Yield
1.99%
Revenue
$44.08M
Earnings
$15.26M
Gross Margin
58.8%
Operating Margin
41.3%
Profit Margin
34.6%
Debt to Equity
0.04
Operating Cash Flow
$17M
Beta
0.57
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

UTMD Overview

Utah Medical Products, Inc. develops, manufactures, and distributes medical devices for the healthcare industry. The company offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. It also provides GESCO umbilical vessel catheters; DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, the company offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; FINESSE+ generators; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies, and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, it provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS endoscopic irrigation devices; suprapubic catheterization; LIBERTY urinary incontinence treatment and control systems; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN tool to manipulate the uterus in laparoscopic procedures. Additionally, the company offers DELTRAN, a disposable pressure transducer; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health centers in hospitals, outpatient clinics, and physician's offices through direct customer service and sales force, independent consultants, and manufacturer representatives. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine UTMD's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

B
Value
F
Growth
C
Momentum
C
Sentiment
C
Safety
B
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Medical

Industry Rating
A
UTMD
Ranked
#31 of 49

Top Ranked Stocks in Industry

View Top Medical Stocks

Be the first to know about important UTMD news, forecast changes, insider trades & much more!

UTMD News

Overview

Due Diligence Score

–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how UTMD scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

UTMD ($60.43) is undervalued by 52.02% relative to our estimate of its Fair Value price of $125.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
UTMD ($60.43) is significantly undervalued by 52.02% relative to our estimate of its Fair Value price of $125.96 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
UTMD ($60.43) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 35 more UTMD due diligence checks available for Premium users.

Valuation

UTMD fair value

Fair Value of UTMD stock based on Discounted Cash Flow (DCF)

Price
$60.43
Fair Value
$125.96
Undervalued by
52.02%
UTMD ($60.43) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
UTMD ($60.43) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
UTMD ($60.43) is trading above... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

UTMD price to earnings (PE)

For valuing profitable companies with steady earnings

Company
14.15x
Industry
40.12x
Market
31x
UTMD is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
UTMD is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

UTMD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.65x
Industry
4.11x
UTMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

UTMD price to earnings growth (PEG)

For valuing profitable companies with growth potential

UTMD is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

UTMD's financial health

Profit margin

Revenue
$10.0M
Net Income
$3.6M
Profit Margin
35.6%
UTMD's Earnings (EBIT) of $18.21M... subscribe to Premium to read more.
Interest Coverage Financials
UTMD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$129.7M
Liabilities
$5.5M
Debt to equity
0.04
UTMD's short-term assets ($101.66M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
UTMD's short-term assets ($101.66M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
UTMD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
UTMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
$3.9M
Investing
-$89.0k
Financing
-$4.9M
UTMD's operating cash flow ($17.23M)... subscribe to Premium to read more.
Debt Coverage Financials

UTMD vs Medical Stocks

TickerZen RatingMarket Cap1d %P/EP/B
UTMDC$204.96M+0.96%14.15x1.65x
STXSC$203.35M-1.23%-8.89x18.80x
KRMDA$213.14M+0.65%-18.60x12.02x
INFUA$172.66M+3.84%135.33x3.11x
ZJYLC$158.11M+22.87%50.50x5.49x

Utah Medical Products Stock FAQ

What is Utah Medical Products's quote symbol?

(NASDAQ: UTMD) Utah Medical Products trades on the NASDAQ under the ticker symbol UTMD. Utah Medical Products stock quotes can also be displayed as NASDAQ: UTMD.

If you're new to stock investing, here's how to buy Utah Medical Products stock.

What is the 52 week high and low for Utah Medical Products (NASDAQ: UTMD)?

(NASDAQ: UTMD) Utah Medical Products's 52-week high was $77.33, and its 52-week low was $58.88. It is currently -21.85% from its 52-week high and 2.64% from its 52-week low.

How much is Utah Medical Products stock worth today?

(NASDAQ: UTMD) Utah Medical Products currently has 3,391,620 outstanding shares. With Utah Medical Products stock trading at $60.43 per share, the total value of Utah Medical Products stock (market capitalization) is $204.96M.

Utah Medical Products stock was originally listed at a price of $6.00 in Mar 8, 1999. If you had invested in Utah Medical Products stock at $6.00, your return over the last 25 years would have been 907.17%, for an annualized return of 9.68% (not including any dividends or dividend reinvestments).

How much is Utah Medical Products's stock price per share?

(NASDAQ: UTMD) Utah Medical Products stock price per share is $60.43 today (as of Feb 10, 2025).

What is Utah Medical Products's Market Cap?

(NASDAQ: UTMD) Utah Medical Products's market cap is $204.96M, as of Feb 11, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Utah Medical Products's market cap is calculated by multiplying UTMD's current stock price of $60.43 by UTMD's total outstanding shares of 3,391,620.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.